Document is current

Any future updates will be listed below

Combination ruxolitinib, belumosudil, and axatilimab yields clinically significant symptomatic improvements in treatment-refractory chronic GVHD

Crossref DOI link: https://doi.org/10.1038/s41409-025-02764-2

Published Online: 2025-11-19

Published Print: 2026-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark